ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes

Benzer Materyaller

• ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response
  Yazar:: Swartjes, Maarten, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density
  Yazar:: Dahan, Albert, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Erratum to: ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density
  Yazar:: Albert Dahan, ve diğerleri
  Baskı/Yayın Bilgisi: (2016-09-01)
• ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats
  Yazar:: Muller, Carole, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study
  Yazar:: Heij, Lara, ve diğerleri
  Baskı/Yayın Bilgisi: (2012)